Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(1):1; doi:10.1093/jnci/97.1.1
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

In This Issue

The first 10% of the full text of this article appears below.

Antidepressant Use and Tamoxifen Metabolism

The efficacy of tamoxifen treatment for breast cancer varies widely among women. The drug is metabolized by several cytochrome P450 (CYP) enzymes, including the CYP2D6 isoform. Some selective serotonin reuptake inhibitors (SSRIs), which are commonly prescribed to treat hot flashes in women who take tamoxifen, are known to inhibit CYP2D6. Jin et al. (p. 30) examined the effects of concomitant SSRI use and CYP2D6 genotypes on plasma concentrations of tamoxifen and its metabolites in women who were undergoing tamoxifen therapy for breast cancer. After 4 months of tamoxifen therapy, women with a CYP2D6 homozygous variant . . . [Full Text of this Article]

CRBP-I Function in Breast Epithelium

VEGFR-3 and New Lymphatic Growth

Zinc Deficiency and Upper Aerodigestive Tract Cancer

Progesterone Receptor Gene and Ovarian Cancer Risk

Bone Turnover Markers and Skeletal Complications


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?